Have glp1 drugs shown benefits in non diabetics

GLP-1 drugs produce substantial weight loss in non-diabetics, but the evidence for other benefits is thinner and comes with significant side effects and costs.

The strongest evidence is for weight loss. In non-diabetic adults with obesity, semaglutide produces mean weight loss of about 10–15% over 6–12 months, with tirzepatide (a dual GIP/GLP-1 agonist) showing even larger reductions, up to 20% [1][2][3]. The SELECT trial, which enrolled over 17,000 non-diabetic people with obesity and cardiovascular disease, found that semaglutide reduced major cardiovascular events by about 20% [4]. This is a real clinical benefit in that specific high-risk population.

But the safety picture matters. Gastrointestinal side effects—nausea, vomiting, diarrhea—are very common, affecting roughly 40–50% of users, and are the main reason people stop treatment [1][7]. Discontinuation rates in trials range from 5–14% [5]. More serious but rarer risks include pancreatitis, gallbladder problems, and a signal for diabetic retinopathy (though this was seen mainly in people with diabetes who had rapid glucose drops) [6][7]. The cost is also a major barrier: semaglutide runs about $800–$1,300 per month in the US, and most insurance does not cover it for weight loss alone [3][7].

What is not proven is whether these drugs provide meaningful benefits for non-diabetics who are merely overweight but otherwise healthy. The weight loss trials enrolled people with obesity (BMI ≥30) or overweight with at least one weight-related complication [1][2]. The cardiovascular benefit was shown in people who already had heart disease [4]. For a healthy person with a BMI of 27 and no other risk factors, the evidence does not show that the benefits of taking these drugs outweigh the side effects, cost, and need for long-term treatment (weight returns when the drug is stopped) [3].

My call: For non-diabetic adults with obesity and established cardiovascular disease, the evidence supports a net benefit from semaglutide. For everyone else without diabetes, the weight loss is real but must be weighed against common side effects, high cost, and the need for indefinite treatment to maintain the loss. Confidence: moderate for weight loss efficacy in obesity, low for benefits in lower-risk populations.